4266-01-7Relevant academic research and scientific papers
Diaryldiamines with dual inhibition of the histamine H3 receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1- phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain
Altenbach, Robert J.,Black, Lawrence A.,Strakhova, Marina I.,Manelli, Arlene M.,Carr, Tracy L.,Marsh, Kennan C.,Wetter, Jill M.,Wensink, Erica J.,Hsieh, Gin C.,Honore, Prisca,Garrison, Tiffany Runyan,Brioni, Jorge D.,Cowart, Marlon D.
supporting information; experimental part, p. 7869 - 7873 (2011/01/12)
A series of compounds was designed as dual inhibitors of the H3 receptor and the norepinephrine transporter. Compound 5 (rNET Ki = 14 nM; rH3R Ki = 37 nM) was found to be efficacious in a rat model of osteoarthritic pain.
NOVEL CENTRAL-NERVOUS SYSTEM ACTING COMPOUNDS AND METHODS FOR THE TREATMENT OF CNS DISORDERS
-
Page/Page column 30, (2010/11/28)
This application relates to a new class of butylamine compounds useful as balanced serotonin/dopamine uptake inhibitors for treating a disease or condition for which inhibition of both serotonin and dopamine reuptake is beneficial, for example, depression
